Venus Medtech Hangzhou saw the highest growth of 2.99% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Venus Medtech Hangzhou‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Venus Medtech Hangzhou has been focused on protecting inventions in European Patent Office(EPO) with six publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 40% filings and 29% grants. The European Patent Office(EPO), United States(US), World Intellectual Property Organization(WIPO), and Canada(CA) patent Office are among the top ten patent offices where Venus Medtech Hangzhou is filings its patents. Among the top granted patent authorities, Venus Medtech Hangzhou has 43% of its grants in United States(US), 29% in European Patent Office(EPO) and 14% in Canada(CA).
Edwards Lifesciences and Boston Scientific could be the strongest competitors for Venus Medtech Hangzhou
In terms of grant share, Venus Medtech Hangzhou stands in fourth position among its competitors. Edwards Lifesciences and Boston Scientific secured the top positions according to recent patent publication data.
Patents related to climate change and emissions reduction lead Venus Medtech Hangzhou's portfolio
Venus Medtech Hangzhou has the highest number of patents in climate change followed by, emissions reduction and cell & gene therapy. For climate change, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Cardiovascular devices related patents lead Venus Medtech Hangzhou portfolio followed by television, and prosthetic heart valves
Venus Medtech Hangzhou has highest number of patents in cardiovascular devices followed by television, prosthetic heart valves, general surgery devices, and orthopedic devices. For cardiovascular devices, nearly 100% of patents were filed and 54% of patents were granted in Q2 2024.
For comprehensive analysis of Venus Medtech Hangzhou's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
